Stockwinners Market Radar for December 10, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:49 EST JinkoSolar board approves upsizing existing buyback program to $350M - JinkoSolar "announced that its board of directors has approved the upsizing and extension of its existing share repurchase program. As previously announced, the Company launched a share repurchase program in July 2022, whereby the Company was authorized to repurchase up to US$200 million of its Class A ordinary shares represented by American depositary shares. In December 2023, the Company extended the share repurchase program by 18 months through June 30, 2025. As of the date of this press release, the Company had repurchased approximately US$134.5 million of the ADSs authorized under the Existing Share Repurchase Program. On December 10, 2024, the Board has approved to upsize the Existing Share Repurchase Program by increasing the aggregate value of Class A ordinary shares represented by ADSs that may be repurchased from $200 million to $350 million. In addition, the Board has also approved to extend the Existing Share Repurchase Program for an additional 12-month period through June 30, 2026. Under the Extended Share Repurchase Program, the Company may repurchase up to approximately US$215.5 million of its Class A ordinary shares represented by the ADSs through June 30, 2026."

19:50 EST Nerdy CEO buys $266.0K in common stock - In a regulatory filing, Nerdy disclosed that its CEO Charles Cohn bought 168.4K shares of common stock on Nerdy on December 6th in a total transaction size of $266.0K. Shares of Nerdy are up 5.3% afterhours at $1.79.

18:26 EST Dave & Buster's sees FY24 adjusted EBITDA $505M-$515M - Says opportunistically refinanced a portion of debt to extend maturities, minimize interest costs, and increase liquidity. Comments taken from Q3 earnings conference call.

17:47 EST Figs up 9% following WSJ report of private equity takeover offer

17:30 EST Cellectar Biosciences trading resumes

17:18 EST Boeing awarded $450.5M Air Force contract - Boeing was awarded a $450.5M undefinitized contract action for the F-15 Japan Super Interceptor Program requirement to incorporate C2 production Lot One. This contract provides for the acquisition of radars, self-protection systems, and mission computer units. Work will be performed in St. Louis, Missouri, and is expected to be completed by February 2030. This contract involves Foreign Military Sales, or FMS, to Japan. This contract was a sole source acquisition. FMS funds in the amount of $110.8M are being obligated at the time of award. The Air Force Life Cycle Management Center is the contracting activity.

17:05 EST Mawson Infrastructure reports November revenue $4.91M, up 2% - Reports November digital relocation revenue $4.18M, up 111%. Reports November combined total current operating hash rate of 4.98 EH/s. Mawson Infrastructure announced its unaudited business and operational update for November. Rahul Mewawalla, CEO and president said, "We are pleased to deliver another month of growth across our businesses with our total monthly revenue increasing year-over-year and month-over-month, highlighted by significant growth in our digital colocation revenue of 111% year-over-year. Following our recent honor of ringing the NASDAQ Closing Bell in celebration of the Company's transformation, we continue to advance our innovative approach to providing digital infrastructure platforms and solutions. Our synergistic business portfolio and our enhanced strategic, operational, and technological capabilities are expected to continue to be a competitive advantage for us moving forward."

17:02 EST Summit Hotel Properties announces pending acquisition of two hotels for $96M - Summit Hotel Properties "announced that it is under contract to acquire the 250-guestroom Hampton Inn Boston - Logan Airport and the 149-guestroom Hilton Garden Inn Tysons Corner for a combined purchase price of $96.0 million, or $241,000 per key. The purchase price represents an 8.8% capitalization rate based on forecasted 2024 net operating income and no meaningful capital expenditures are planned prior to the fourth quarter of 2026."

17:00 EST Acelyrin Inc trading resumes

16:55 EST Cellectar Biosciences trading halted, news pending

16:36 EST Toro Company raises dividend 2c to 38c - The Toro Company announced that its Board of Directors has declared a regular quarterly cash dividend of 38c per share of TTC's common stock, an increase over the previous quarter's cash dividend of 36c per share of TTC's common stock. This marks the 16th consecutive year that the company has increased its dividend. The dividend is payable on January 13, 2025, to shareholders of record at the close of business on December 23.

16:34 EST MAA raises quarterly dividend 3.1% to $1.515 per share - Mid-America Apartment Communities announced that its board of directors approved a quarterly dividend payment of $1.515 per share of common stock to be paid on January 31, 2025, to shareholders of record on January 15, 2025. The increase will raise the annualized dividend payment 3.1% to $6.06 per share of common stock and represents the 15th consecutive year MAA has increased its dividend to shareholders.

16:32 EST Stitch Fix jumps 18% to $5.45 after Q1 earnings beat, above-consensus guidance

16:31 EST MAA raises quarterly dividend to 3.1% $1.515 per share - Mid-America Apartment Communities announced that its board of directors approved a quarterly dividend payment of $1.515 per share of common stock to be paid on January 31, 2025, to shareholders of record on January 15, 2025. The increase will raise the annualized dividend payment 3.1% to $6.06 per share of common stock and represents the 15th consecutive year MAA has increased its dividend to shareholders.

16:30 EST Spruce Biosciences Inc trading resumes

16:27 EST Artisan Partners reports AUM, as of November 30 totals $166.8B - Artisan Partners Asset Management reported that its preliminary assets under management or AUM, as of November 30, totaled $166.8B. Artisan Funds and Artisan Global Funds accounted for $80.5B of total firm AUM, while separate accounts and other AUM1 accounted for $86.3 B. In November, certain Artisan Funds made their annual income and capital gains distributions. November month-end AUM includes the impact of approximately $314 million of Artisan Funds distributions not reinvested.

16:25 EST Acelyrin Inc trading halted, news pending

16:22 EST Booking Holdings sees expense reduction of $400M-$450M from efficiency steps - In a regulatory filing, Booking Holdings states: "On November 8, 2024, the Company announced its intention to implement certain organizational changes that are expected to improve operating expense efficiency, increase organizational agility, free up resources that can be reinvested into further improving its offering to travelers and partners, and better position the Company for the long term. We estimate that the Program will, over the coming three years, ultimately reduce annual run rate expenses by approximately $400 to $450 million versus our 2024 expense base. We expect the majority of these savings to come from changes across our brands such as modernizing processes and systems, optimizing procurement, and reducing real estate footprint, as well as approximately one-third from expected workforce reductions. We expect the majority of the estimated savings to be realized after 2025, and the annualized run rate savings do not reflect the aggregate expected costs to implement the Program. We believe these actions will help us towards our goal of growing fixed expenses slower than revenue in 2025 and improving efficiency across other operating expenses. We currently expect that restructuring costs and accelerated investments related to the Program will be incurred in the next two to three years and are estimated to be, in the aggregate, approximately one times the expected annual run rate saving. We anticipate these costs to primarily relate to expected workforce reductions, technology investments, and professional fees."

16:19 EST Apollomics regains compliance with Nasdaq minimum bid rule - Apollomics announced that on December 10 it received a notification from The Nasdaq Stock Market LLC stating that the Company has regained compliance with the requirement to maintain a minimum closing bid price of $1.00 per share, as set forth in Nasdaq Rule 5550(a)(2) and Nasdaq has determined to continue the listing of the Company's Class A ordinary shares on the Nasdaq Capital Market under the symbol "APLM."

16:18 EST Optex Systems receives $2M in orders supporting Night Vision devices - Optex Systems Holdings announced it has been awarded a new contract for Laser Filter Units and Window Assemblies supporting Night Vision devices utilized by the U.S. Armed Forces. The order value is $2.0M with deliveries covering March 2025 through February 2026. "The AOC team is pleased to continue our support of optical assemblies supporting various Night Vision Devices. AOC has positioned itself as a key supplier of laser protection filters and assemblies supporting the primary suppliers of Night Vision equipment to the U.S. military. We have recently added critical infrastructure to ensure we can continue to meet the growing demand for specialized laser filters and other coated optics" stated Bill Bates, General Manager of Applied Optics Center. With this new order, the current Optex backlog is in excess of $42million.

16:17 EST Mantle Ridge nominates four directors to Air Products' board - Mantle Ridge LP, which, together with its affiliates, beneficially owns approximately $1.3B of the outstanding common shares of Air Products and Chemicals, announced that it has filed a definitive proxy statement formally nominating four highly qualified director candidates for election to Air Products' Board of Directors at the company's 2025 Annual Meeting of Shareholders. Reference Link

16:16 EST Morningstar names Michael Holt CFO - Morningstar, Inc. announced the appointment of Michael Holt as chief financial officer, effective January 1, 2025. The company previously announced that Jason Dubinsky would step down at the end of the year and assume a consulting role through a transition period. Reporting to chief executive officer Kunal Kapoor, Holt will lead and oversee Morningstar's global finance organization. He has served as Morningstar's chief strategy officer for the past seven years and, in 2023, was also named president of the Research and Investments group, overseeing the 400-person team responsible for Morningstar's rigorous, independent equity and managed investment analysis and ratings as well as portfolio construction for the company's investment management capabilities. "Mike is a proven strategist, analyst, and leader of high-performing teams," Kapoor said. "Mike intensely focuses on value creation and draws a direct line from strategy to outcomes and financial accountability. His extensive operational knowledge of our firm and ability to partner across the business to support continued durable growth make him the right fit for our next CFO."

16:15 EST Sportsman's Warehouse sees FY24 revenue $$1.18B -$1.20B, consensus $1.15B - "Given the current consumer environment and the shift towards value and promotion-driven shopping, we intensified our marketing and advertising campaigns to drive sales, which placed additional pressure on our margins this quarter," said Jeff White, Chief Financial Officer of Sportsman's Warehouse "To ensure strong core product in-stocks and to bring fresh offerings to our stores, we made strategic inventory investments aimed at improving sales during the hunting and holiday seasons. As we progress through the remainder of the year, we will remain disciplined in managing our expenses, and will reduce total inventory levels to generate positive free cash flow. Our mid and long-term objectives will be centered on improving our topline with a focus on margins and profitability."The Company is adjusting its guidance for fiscal year 2024 and expects net sales to be in the range of $1.18B to $1.20B, adjusted EBITDA to be in the range of $23M to $29M and total inventory to be below $350M. The low end of the adjusted EBITDA range still assumes positive free cash flow for the full year. The Company now expects capital expenditures for 2024 to be in the range of $17 M to $20M, primarily consisting of technology investments relating to merchandising and store productivity. No new store openings for the remainder of fiscal year 2024 are currently anticipated and we plan to open one new store in fiscal year 2025.

16:12 EST Darling Ingredients announces Avfuel takes first delivery of SAF - Darling Ingredients (DAR) announced that Avfuel, the supplier of aviation fuel and services, took the first delivery of sustainable aviation fuel, or SAF, produced by Diamond Green Diesel, or DGD, a 50/50 joint venture between Darling Ingredients and Valero Energy Corporation (VLO). Naples Aviation, or KAPF, accepted Avfuel's delivery of SAF, marking the fuel supplier's first network location to offer SAF for general sale in the eastern United States. Naples Aviation's SAF delivery comes on the heels of a SAF supply agreement between Avfuel and Valero Marketing and Supply Company, a subsidiary of Valero. DGD's Port Arthur, Texas, facility loaded its first SAF shipment on November 16. The facility has converted approximately 50% of its annual 470 million gallon capacity to SAF and is expected to be one of the largest SAF manufacturers in the world.

16:09 EST General Motors to raise ownership of Cruise to more than 97%

16:08 EST GM says will no longer fund Cruise's robotaxi development work

16:08 EST GE Vernova approves initial $6B share repurchase authorization - GE Vernova's strategic principles for capital allocation include incremental organic investments to drive profitable growth, returning at least one third of cash generation to shareholders, and targeted, bolt-on mergers and acquisitions along with select next-generation technology investments. The GE Vernova Board of Directors has declared a $0.25 per share quarterly dividend, payable on January 28, 2025 to shareholders of record as of December 20, 2024, and approved an initial $6B share repurchase authorization.

16:05 EST Athena Technology Acquisition Corp II trading halted, news pending

16:00 EST Spruce Biosciences Inc trading halted, news pending

15:34 EST U.S. Steel down 9% after Bloomberg says Biden set to block Nippon Steel deal

15:29 EST US Steel trading halted, volatility trading pause

15:26 EST Kroger moves up, Albertsons falls after Bloomberg says deal blocked by judge

15:24 EST YouTube debuts multiplayer mini-games on Playables - Google's YouTube announced a new feature in its Playables app that allows users to try a multi-player function in real-time. The company said earlier: "We're beginning to test a new multiplayer feature for a few select games on YouTube Playables. Multiplayer on Playables lets you play games in real-time with other users. We're starting our tests with two games: Ludo Club and Magic Tiles 3 on desktop and mobile devices. We're just getting started testing out new features for YouTube Playables with more to come in the future." Reference Link

15:18 EST Theratechnologies gets March 2025 PDUFA date for tesamorelin F8 formulation sBLA - Theratechnologies announced that the United States FDA has assigned a Prescription Drug User Fee Act goal date of March 25, 2025 to the company's recently submitted supplemental Biologics License Application for the F8 formulation of tesamorelin. If approved by the FDA, the F8 formulation is intended to replace the F4 formulation, which is sold in the U.S. under the trade name EGRIFTA SV. The new formulation is patent protected in the U.S. until 2033.

14:59 EST AbbVie treatment of multiple myeloma granted FDA orphan designation - AbbVie was granted FDA orphan designation for a treatment of multiple myeloma, according to a post to the agency's website. Reference Link

14:34 EST Instagram debuts new feature for creators to test experimental reels - In an earlier release on Tuesday, Instagram said that Trial reels are a new way to try out content and see what performs best by sharing reels with people who don't follow you....Instagram added, in part:..."we're introducing trial reels, a new way to try out content and see what performs best by sharing reels with people who don't follow you. If you've ever wanted to experiment with new ideas without worrying about how your followers might react, trial reels are the tool you've been looking for. Trial reels help take the guesswork out of how your content will perform. See If Content Resonates Before Sharing It With Your Followers... We often hear from creators that they feel nervous about posting too much or trying out content that's outside of their niche on Instagram, for fear of it not resonating with their followers. Trial reels will be shown to non-followers first. Now, if you want to try out a new genre, storytelling format or topic, you can easily get a gut check on how your content might perform. If you feel good about a trial reel and how it's performing, you can choose to share it with your followers with one tap or decide to set up the reel so that once the trial is over, if it's performed well, it gets automatically shared with your followers. " Reference Link

14:24 EST Garmin dips after Bloomberg report on sattelite-enabled Apple Watch Ultra - Shares of Garmin (GRMN) are fractionally lower in afternoon trading after Bloomberg's Mark Gurman reported earlier, citing sources, that Apple (AAPL) plans to bring satellite connections to its next Apple Watch Ultra in 2025, relying on satellites from Globalstar (GSAT). "The Apple Watch Ultra would be the first mainstream smartwatch with satellite abilities. The move also could give consumers less reason to use a standalone satellite communication device, such as Garmin Ltd.'s inReach," Gurman stated. Reference Link

13:55 EST Markel up 1% to $1,772 after Jana takes stake, pushes for separation

13:40 EST TransMedics down 3% during analyst day meeting - Shares of TransMedics, whose investor and analyst day began at 10 am ET, are down about 3% to $67.46 in afternoon trading.

13:36 EST Shyft Group announces first shipments of Blue Arc Class 4 EV truck to customers - The Shyft Group announced the first shipments of its Blue Arc Class 4 EV truck to multiple customers, including initial deliveries to a leading parcel delivery customer. These shipments mark the transition to regular production to meet demand for electrified fleet solutions."This is an exciting and proud moment for the Blue Arc team," said John Dunn, President and CEO of the Shyft Group. "What started in 2021 as a bold vision for fleet electrification has become a reality thanks to the dedication, expertise, and collaboration of our team. Together, we've delivered a commercial-grade vehicle that meets the demanding standards of our fleet partners and supports their transition to more sustainable fleet operations." These shipments are the result of three years of customer collaboration, rigorous testing, and advanced manufacturing development. Created through Shyft's Work-Driven Design process, the Blue Arc Class 4 EV truck reflects input from fleet operators and drivers, ensuring it prioritizes reliability, comfort, and versatility.

13:03 EST Engaged Capital says 'compelling idea' NCR Voyix trades at extreme discount - Activist investor Engaged Capital named NCR Voyix as a "compelling investment idea." Engaged Capital said in a presentation at the Bloomberg Activism Forum 2024 that it believes NCR Voyix trades substantially below fair value, restaurant competitive concerns are overblown and that it sees significant upside from current prices. Trading just at the bottom end of peer valuations would result in almost a double, it says, adding that it sees potential for a 95% upside. Reference Link

12:55 EST Matthews responds to Barington, says operating results 'solid' - Matthews International issued a statement in response to the recent statement and nomination notice the company has received from Barington Capital Group, stating in part: "Our recent operating results reflect solid performance by our core businesses and demonstrate the resilience of our team in the face of a challenging market environment. As a result of strong execution and oversight by the Matthews Board of Directors and management team, the fundamentals of our businesses and their long-term outlook are strong: Memorialization has benefited from pricing actions and several smaller strategic acquisitions, while delivering on cremation and mausoleum-related products that underscore the segment's long-term commitment to diversify its best-in-class offerings within the deathcare industry. Cost control measures taken during the fiscal year have also contributed to an improvement in operating margins; SGK recently reported its third consecutive quarter of higher sequential sales and solid margins. Notably, the strategic decision to invest in resources to support the transitioning of components of our core business to an e-commerce digital marketing platform differentiates us from our peers and led to an increase in revenues and organic business opportunities that position us well for 2025; Within Industrial Technologies we expect the demand recovery to have a positive impact at the start of our new fiscal year, which should result in meaningful revenue results in the latter part of fiscal 2025 and into 2026; Interest in the innovative solutions being offered through our Energy Solutions business remains strong, and we are well positioned both financially and operationally to lead the ongoing transition to electric vehicles through our multi-decade investment in advanced rotary processing technologies and alternative solutions for such technologies... The Matthews Board and management team are committed to serving in the best interests of all our shareholders, and as the evaluation of strategic alternatives underscores, we will continue to take actions that are in the best interests of driving long-term value creation for all our shareholders."

12:45 EST Paccar announces extra cash dividend of $3.00 per share - Paccar Board of Directors declared an extra cash dividend of $3.00 per share, payable on January 8, 2025, to stockholders of record at the close of business on December 20, 2024. Mark Pigott, executive chairman, shared, "PACCAR has generated excellent shareholder returns due to its industry-leading vehicles, strong growth in aftermarket parts and financial services, and innovative use of technology to enhance customers' operational performance."

12:42 EST Walgreens resumes trading, shares up 25% to $11.05 after WSJ report

12:33 EST Walgreens jumps 6% to $9.38 after WSJ report of sale talks

12:11 EST Boise Cascade announces acquisition of Parksite door shop in Lakeland, Florida - Boise Cascade Company announced that it has purchased the assets of the Parksite door shop in Lakeland, Florida. Parksite currently has 22 locations, and this transaction involves their Florida door shop only. The remaining Parksite locations and products are not part of this agreement and will continue to be owned and operated by Parksite. The transaction was completed on Tuesday.

12:04 EST United Natural Foods rises 25.4% - United Natural Foods is up 25.4%, or $6.26 to $30.94.

12:04 EST BigBear.ai falls -11.7% - BigBear.ai is down -11.7%, or -43c to $3.23.

12:00 EST Surf Air Mobility falls -20.9% - Surf Air Mobility is down -20.9%, or -91c to $3.45.

11:47 EST KeyCorp says economy picking up, sees opportunities to deploy capital

11:42 EST KeyCorp says to focus on fee-based businesses in 2025

11:38 EST KeyCorp CEO sees 'very solid' Q4 - Says credit metrics solid and improving. Comments taken from the Goldman Sachs Financial Services Conference.

11:12 EST Expedia appoints Shilpa Ranganathan as Chief Product Officer - Expedia (EXPE) announced the appointment of Shilpa Ranganathan as the company's Chief Product Officer, marking her return to Expedia Group to lead the product and design teams. Most recently, she was Corporate Vice President at Microsoft (MSFT), leading the Windows end-user, developer, and marketplace teams, the company noted. "We're thrilled to welcome Shilpa back to Expedia Group as Chief Product Officer. She brings extensive experience in building consumer products based on customer needs and leveraging cutting-edge technology. Shilpa's passion for travel and expertise in product development will be invaluable as we continue to create new experiences for our travelers and partners," said Ariane Gorin, Chief Executive Officer, Expedia Group.

10:21 EST AIM ImmunoTech says Glass Lewis recommends shareholders vote for nominees - AIM ImmunoTech announced that independent proxy advisory firm Glass, Lewis & Co., LLC has recommended that shareholders vote "FOR" company nominees Nancy K. Bryan, Thomas K. Equels and Dr. William M. Mitchell at the upcoming 2024 Annual Meeting of Stockholders, presently scheduled for December 17, 2024. In reaching its recommendation against giving the activist investors' nominees control of the AIM Board of Directors, Glass Lewis noted the following: "...the [Activist Group's] presented plan lacks substantive detail. For instance, it does not provide for a particular clinical strategy and relies on a full review of Ampligen's indications to define such strategy, lacks a clear view on the Company's management going forward, and does not indicate the less dilutive and less expensive financing options that may be available to the Company." "... we do not believe the Dissident Group presented a fully qualified board slate of candidates to justify shareholder support of all four nominees."

10:04 EST Goldman CFO sees 'elevated' M&A optimism, CEO confidence post-election

10:03 EST Goldman Sachs CFO says 'no question' U.S. economy has proved to be resilient - CFO Denis Coleman is speaking at the firm's U.S. Financial Services Conference.

10:01 EST Yext falls -15.3% - Yext is down -15.3%, or -$1.30 to $7.22.

10:00 EST MoneyLion rises 14.0% - MoneyLion is up 14.0%, or $10.75 to $87.76.

10:00 EST Trinseo rises 22.8% - Trinseo is up 22.8%, or $1.01 to $5.47.

09:49 EST Synchrony says quarter-to-date spending 'a little bit lighter' than expected - While presenting at the Goldman Sachs U.S. Financial Services Conference, Synchrony CEO Brian Doubles and CFO Brian Wenzel were asked what spending looks like quarter-to-date and about any noticeable differences from prior quarters, to which the executives replied in part: "When you think about the growth of the business, we reported this morning end of period loans up 1.7%. So you did see a little bit of seasonal tick up October-November, in all honesty, a little bit lighter than our expectations. As we entered into the quarter and a lot of that was more in the October timeframe, where we thought it was going to - we're going to see a little bit more of a ramp up as we moved towards the holiday season. Didn't necessarily happen, but it's been relatively stable... Obviously, this is all impacted by the modest credit actions that we put in place, both on a volume side and in new account side. So, what's a little bit unclear is you have less days and one less weekend days as we get towards actual Christmas. So, we're constructive now. But again, a little bit lighter than our expectations."

09:47 EST Voya sinks 5% to $75.57 after stop loss guidance disappoints

09:47 EST MoneyLion rises 13.9% - MoneyLion is up 13.9%, or $10.74 to $87.75.

09:47 EST ATRenew falls -12.5% - ATRenew is down -12.5%, or -44c to $3.08.

09:47 EST Yext falls -14.6% - Yext is down -14.6%, or -$1.24 to $7.28.

09:43 EST Immix Biopharma reports 75% CRR for NXC-201 in r/r AL amyloidosis patients - Immix Biopharma announced that new NXC-201 NEXICART-1 clinical data in relapsed/refractory AL Amyloidosis has been presented at 66th American Society of Hematology Annual Meeting being held in San Diego, California. The updated results include follow-up and clinical data from 3 new NEXICART-1 patients. "We are encouraged by the updated NXC-201 results being presented by our academic collaborators at ASH 2024. We believe the high percentage of complete responders, combined with the consistent, attractive tolerability profile is critically important in relapsed/refractory AL Amyloidosis. This expanded NXC-201 dataset continues to bolster our leadership in relapsed/refractory AL Amyloidosis, where no drugs are FDA approved today," said Ilya Rachman, M.D., Ph.D., CEO of Immix Biopharma. At the NXC-201 ASH 2024 oral presentation, data were presented from 16 relapsed/refractory AL amyloidosis patients (including 3 new patients) in the ongoing Phase 1b/2 NEXICART-1 study, with median 4 lines of therapy prior to NXC-201. Patients were infused with CAR+T cells at doses of 150 x 106 (n=1), 450 x 106 (n=2), and 800 x 106 (n=13). Safety and efficacy data: Overall response rate of 94% (15/16); Complete response rate of 75% (12/16) (9 out of 16 were MRD- 10-5); Organ response rate of 62% (8/13 evaluable); Best responder had a duration of response of 31.5 months as of December 9, 2024, with complete response ongoing; There were no immune effector cell-associated neurotoxicity syndrome events.

09:41 EST Trimble sees regaining compliance with Nasdaq listing rules

09:40 EST Falcon's Beyond Global Inc trading resumes

09:38 EST Ming Shing Group Holdings Ltd trading resumes

09:33 EST Ming Shing Group Holdings Ltd trading halted, volatility trading pause

09:30 EST Falcon's Beyond Global Inc trading halted, volatility trading pause

09:28 EST Actelis Networks secured significant new order for City of SDOT - Actelis Networks announced that it has secured a significant new order for the City of Seattle Department of Transportation, SDOT. This milestone further cements Actelis' role in critical infrastructure modernization across the U.S. and globally, following recent wins in Washington, D.C., San Jose and major international cities.

09:27 EST Atossa Therapeutics announces three posters on Phase 2 EVANGELINE trial - Atossa Therapeutics announced that three posters involving pharmacokinetic and tolerability data from the Phase 2 EVANGELINE trial will be presented at the 2024 San Antonio Breast Cancer Symposium, SABCS 2024. The first poster, "Neoadjuvant Z-Endoxifen for Premenopausal Estrogen Receptor (ER)+, Human Epidermal Receptor- Breast Cancer: Evaluation of the Pharmacokinetic Run-in for the EVANGELINE Study," discusses findings from the pharmacokinetic run-in phase of the trial. Primary Endpoint Achieved: 50 percent of patients in the group that received 80 mg of (Z)-endoxifen with goserelin met the target steady-state plasma concentrations of 500-1000 ng/mL. The second poster, "Evaluation of Quality of Life Measures in the EVANGELINE Study," focuses on patient-reported outcomes from (Z)-endoxifen treatment in patients enrolled onto the PK run-in. The QOL data presented supports (Z)-endoxifen as generally well-tolerated. The third poster, "A Randomized Phase 2 Non-inferiority Trial of (Z)-endoxifen and Exemestane + Goserelin as Neoadjuvant Treatment for Premenopausal Women with ER+/HER2- Breast Cancer." Based on adverse events reported in 80 mg/day groups, as well as the findings reported on (Z)-endoxifen tissue and plasma Css, overall tolerability, and antitumor activity, EVANGELINE is expected to proceed based on an amended protocol as a randomized trial that compares (Z)-endoxifen 40 mg/day plus OFS to exemestane plus OFS, using the 4-week Ki-67 reduction as the primary endpoint.

09:23 EST Arvinas, Pfizer announce initial Phase 1b data from TACTIVE-U sub-study - Arvinas (ARVN) and Pfizer (PFE) announced preliminary data from the ongoing Phase 1b portion of the TACTIVE-U sub-study of vepdegestrant in combination with abemaciclib among patients with locally advanced or metastatic estrogen receptor positive/human epidermal growth factor receptor 2 negative breast cancer. These data will be presented in a poster at the 2024 San Antonio Breast Cancer Symposium, SABCS, in San Antonio, Texas. Preliminary results from 16 patients in the Phase 1b sub-study demonstrated a tolerable safety profile for the combination of abemaciclib 150 mg twice daily with the recommended Phase 3 monotherapy dose of vepdegestrant. An encouraging clinical benefit rate of 62.5% was observed among patients with both mutant ESR1 and wild-type ESR1 disease who had all been previously treated with a CDK4/6 inhibitor.

09:19 EST Fortune Brands Innovations boosts dividend to 25c per share - Fortune Brands Innovations announced that on December 9 its Board of Directors declared a quarterly cash dividend of 25c per common share. The dividend is payable on March 12 to stockholders of record as of the close of business on February 21. The increase in the quarterly dividend, from 24c to 25c, represents the Board's continued confidence in the Company's long-term cash flow potential and its support of the Company's broader strategy for utilizing free cash flow to build shareholder value by investing in Fortune Brands' businesses, pursuing accretive acquisitions and returning cash to shareholders.

09:18 EST Rigetti Computing, Quantum Machines announce AI-powered calibration - Quantum Machines, the leading provider of processor-based quantum controllers and Rigetti Computing announced the successful application of AI to automate the calibration of a quantum computer. The work was completed as part of the "AI for Quantum Calibration Challenge" that was jointly issued by Rigetti and Quantum Machines and hosted at the Israeli Quantum Computing Center, IQCC.

09:16 EST Taboola signs new content recommendation deal with Future - Taboola announced the renewal of its long-standing partnership with Future, a global multi-platform media company and leading digital publisher of specialist media. The new agreement takes Taboola's relationship with Future into its 12th year. In the new deal, Future will continue to implement Taboola's suite of products to help grow its audience, optimise user engagement and drive revenue across its large portfolio spanning multiple sectors including technology, entertainment, and lifestyle.

09:11 EST Broadcom announces introduction of Bitnami Premium - Broadcom announced the introduction of Bitnami Premium, a commercial enterprise version of Bitnami by VMware Tanzu. The company also named Arrow Electronics, a leading technology solutions and services company, as a global distributor of Bitnami Premium.

09:10 EST Neuraxis announces FDA 510k clearance of RED for testing, evaluation - NeurAxis announced the US Food and Drug Administration, FDA, granted a 510(k) clearance for RED, Rectal Expulsion Device, allowing NeurAxis to commercially market the device for testing and evaluation of patients with chronic constipation due to pelvic floor dyssynergia and who are unlikely to improve with increased laxative use.

09:09 EST ALX Oncology announces results from Phase 1b/2 trial - ALX Oncology (ALXO) announced results from a Phase 1b/2 clinical trial demonstrating the company's investigational CD47-blocker evorpacept in combination with Jazz Pharmaceuticals' (JAZZ) zanidatamab generates promising anti-tumor activity in patients with both HER2-positive and HER2-low advanced breast cancer. Key trial results to be shared at SABCS 2024 include: HER2-positive by central assessment mBC: Patients in Cohort 1 who were HER2-positive by central assessment showed the greatest anti-tumor activity with a confirmed objective response rate of 55.6% and a median progression free survival of 7.4 months. HER2-positive mBC: Overall, patients in Cohort 1 had a confirmed cORR and mPFS of 33.3% and 3.6 months, respectively. HER2-low mBC: Responses were also observed in Cohort 2. As of the August 2024 data cutoff, median follow-up was 9.6 months, with six patients still on treatment. The median duration of response was not reached for Cohort 1 patients and was 5.5 months for Cohort 2 patients, with responses ongoing, including the longest observed response, in each cohort.

09:07 EST Rambus extends patent license agreement with Micron - Rambus (RMBS) announced it has extended the term of its patent license agreement with Micron (MU) for an additional five years. The extension maintains the existing licensing terms, providing Micron with broad access to the Rambus patent portfolio through late 2029. Other terms and details are confidential.

09:06 EST Getty Images to provide AI-generated visuals for Clarifai platfform - Getty Images and Clarifai, a provider of AI orchestration and development and pioneer of the full-stack computer vision platform, announced a strategic engagement that integrates Getty Images' generative AI capabilities into the Clarifai platform. Through this collaboration, Clarifai's enterprise customers will gain direct access to responsibly developed generative AI-powered visuals powered by an API of Generative AI by Getty Images. Powered by NVIDIA AI and Edify and trained exclusively on Getty Images' creative library, the integration with Generative AI by Getty Images will allow Clarifai customers to create content tailored to their needs, while ensuring responsible usage that is legally protected. Clarifai enterprise customers can access initial trial operations for free, followed by discounts at higher volumes.

09:05 EST Bragg Gaming announces insider share purchases - Bragg Gaming announced insider share purchases. Bragg also emphasized that strategic growth and liquidity initiatives remain key priorities following the Board's Strategic Alternatives Process conclusion. "The recent insider purchases by Bragg's management and board underscore our confidence in the company's near-term potential. We remain committed to creating shareholder value and liquidity opportunities over the next year through strategic transactions, or other value-enhancing initiatives. While the strategic review process has concluded, our dedication to pursuing these objectives heading into 2025 remains unchanged. Furthermore, the strategic review process provided invaluable insights into the key factors potential acquirers prioritize when crafting bids that accurately reflect our intrinsic value. We've identified key focus areas, such as stronger cash generation, increased revenue diversification, accelerated proprietary content growth, and enhanced margins. These are tangible, actionable targets that have been at the heart of our strategic initiatives, and we believe are achievable under our 2025 plan. The alignment between management's insider purchases and our strategic roadmap demonstrates that we're not just talking about value creation - we're investing alongside our shareholders while actively pursuing paths to enhanced liquidity. While the formal review process has concluded, it has sharpened our focus on the metrics that matter most. These concrete objectives, combined with our ongoing commitment to explore opportunities that could provide meaningful liquidity events for our investors, strengthen our position. As insiders, we clearly see the potential to see this value realized in 2025."

09:03 EST Cognizant and Zscaler expand partnership for AI-enabled security - Cognizant (CTSH) and Zscaler (ZS) are expanding their partnership with the goal of helping enterprises across industries simplify and transform their security posture with an AI-enabled zero trust cloud security platform to address evolving cyber threats. Under the expanded partnership, Cognizant and Zscaler will offer coordinated solutions and services designed to reduce overall security complexity, maximize security posture, and deliver comprehensive, cost-effective outcomes rapidly and at scale.

09:02 EST Ferrari enters multi-year agreement with Andretti Formula Racing - Ferrari N.V. announces a multi-year agreement starting from 2026 with Andretti Formula Racing, regarding the supply of power unit and gearbox to the racing team led by TWG Global and General Motors, subject to Andretti Formula Racing LLC receiving written confirmation from the FIA - F1 that its entry to the 2026 FIA Formula One Championship has been accepted and approved.

09:01 EST TSMC reports November revenue NT$276.1B, up 34% y/y - TSMC revenue for January through November 2024 totaled NT$2.62T, an increase of 31.8% compared to the same period in 2023.

09:00 EST Citi CFO says not seeing anything unexpected in card delinquencies

08:59 EST Citi CFO: 2024 has been better than expected for NII ex-Markets

08:57 EST Sabre and American Airlines extend IT partnership - Sabre (SABR) and American Airlines (AAL) announced the multi-year renewal of their technology partnership, including the provision of the SabreSonic Passenger Service System. In addition to renewing the SabreSonic agreement, American has extended its subscription with Sabre PRISM, a corporate travel contract management solution. These agreements follow last year's announcement of availability of American's NDC offers through Sabre's Global Distribution System. Last week, Sabre and American resolved litigation in connection with a 2011 lawsuit initiated by US Airways.

08:44 EST Atlantica Sustainable acquisition by Energy Capital sanctioned by High Court - Atlantica Sustainable Infrastructure announced that the High Court of Justice of England and Wales has sanctioned the scheme of arrangement providing for the proposed acquisition of the Company by California Buyer Limited, Bidco, a vehicle controlled by funds managed by Energy Capital Partners, ECP, and which includes a large group of institutional co-investors.

08:43 EST Reborn Coffee announces collaboration with Finlays - Reborn Coffee announced a collaboration with Finlays, a global leader in premium tea and coffee solutions, launching its new ready-to-drink 4th Wave Cold Brew product line during Art Basel Miami Beach 2024, which took place December 6-8, 2024.

08:41 EST Silexion Therapeutics appoints Peled to board of directors - Silexion Therapeutics announced the appointment of Prof. Amnon Peled as an independent director to its Board of Directors.

08:39 EST Ahold Delhaize, Campbell's launch regenerative agriculture pilot - Ahold Delhaize USA (ADRNY) has announced another Scope 3 pilot program - this time focused on the potato crop. Over the next three years, the company will work with The Campbell's Company (CPB) to reduce Scope 3 greenhouse gas emissions associated with potato farming. This collaboration will support partner farms to implement regenerative farming techniques to create more resilient agricultural systems and reduce carbon emissions through soil health practices and other opportunities.

08:37 EST Tourmaline Bio provides updates on TRANQUILITY trial, SAB - Tourmaline Bio is hosting its Investor Day. Tourmaline today is announcing the over-enrollment of its Phase 2 TRANQUILITY trial, which evaluates quarterly and monthly subcutaneous dosing of pacibekitug in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease. Tourmaline expects to report topline data from this trial in the second quarter of 2025. Expansion of Cardiovascular Scientific Advisory Board, SAB, with two new appointments: Deepak L. Bhatt; Dipender Gill.

08:35 EST AgriFORCE Growing Systems signs LOI to acquire Bitcoin mining facility - AgriFORCE Growing Systems has signed a Letter of Intent, LOI, to acquire a Bitcoin mining facility in Madison Township, Ohio. The facility is powered by sustainable energy, advancing AgriFORCE's mission to integrate innovative technologies that promote environmental stewardship while generating significant financial returns.

08:33 EST Sellas Life Sciences triggers interim analysis in Phase 3 REGAL trial - SELLAS Life Science announced that the pre-specified threshold of 60 events has been reached in its ongoing Phase 3 REGAL clinical trial of galinpepimut-S, GPS, in acute myeloid leukemia, AML, triggering the interim analysis to be conducted by the Independent Data Monitoring Committee, IDMC.

08:31 EST KVH Industries selected by Seaspan to equip fleet with OneWeb LEO solution - KVH Industries announced that Seaspan Corporation, a world leading independent containership lessor, has signed an agreement to equip its fleet with the OneWeb advanced low earth orbit, LEO, satellite offering from KVH. This marks the next step in Seaspan's drive to deliver shore-like Internet connectivity at sea, supporting its digital transformation strategy and augmenting its fleet's existing LEO services.

08:30 EST Imunon announces additional data from results from Phase 2 OVATION 2 study - IMUNON announced additional clinical data from ongoing analyses of results from the Company's Phase 2 OVATION 2 Study of IMNN-001, its investigational interleukin-12 immunotherapy for the treatment of advanced ovarian cancer based on its proprietary TheraPlas technology. The updated results, based on an additional seven months of patient monitoring, show the hazard ratio decreased from 0.74 to 0.69, with an increase in median overall survival from 11.1 to 13 months following treatment with IMNN-001 plus standard-of-care neoadjuvant and adjuvant chemotherapy versus SoC alone. More than one-third of patients in the trial survived more than 36 months from the point of study enrollment, with 62% of those surviving patients from the IMNN-001 treatment arm and 38% from the SoC arm. Over 10% of trial participants have reached 48 months or beyond.

08:28 EST NextCure announces acceptance of IND application for LNCB74 - NextCure announced that the U.S. Food and Drug Administration, FDA, accepted an Investigational New Drug, IND, application for initiation of a Phase 1 clinical trial to evaluate LNCB74, a B7-H4-targeting antibody-drug conjugate, ADC, as a therapeutic for treating multiple cancers. "Acceptance of the IND application for LNCB74 represents an important milestone for NextCure as we focus our resources on advancing our ADC program," said Michael Richman, NextCure's president and CEO. "The IND application leverages LNCB74 preclinical data that highlights the differentiation of our B7-H4 ADC from other ADCs targeting B7-H4. We believe LNCB74 has the potential to transform treatment for patients and we look forward to advancing LNCB74 into clinical development."

08:24 EST Sandstorm Gold authorizes share repurchase plan, renews credit facility - Sandstorm Gold provided corporate updates related to the company's share repurchase program and revolving credit facility agreement. The company has entered into an Automatic Share Purchase Plan with its designated broker to facilitate the purchase of the company's issued and outstanding common shares under its Normal Course Issuer Bid. The ASPP will facilitate purchases under the NCIB at times when the company would ordinarily not be permitted to make purchases. The company may purchase up to 20.0 million of its Common Shares. The ASPP provides for the purchase of up to 10.0 million of the company's Common Shares and purchases made under the ASPP must comply with TSX rules and will count towards the limit set by the NCIB. Since the commencement of the NCIB on May 7, 2024, the company has purchased 1,578,800 Common Shares at a volume-weighted average price of C$7.58 per Common Share on the TSX and approximately US$5.47 per Common Share on the NYSE. The company has renewed its revolving credit agreement allowing the company to borrow up to $625M. The revised interest rates above SOFR represents a 75-basis point reduction at the upper end and a reduction of 12.5 basis points at the lower end when compared to the previous credit agreement. The Revolving Credit Facility has a term of four years, maturing in December 2028.

08:22 EST Myriad Genetics' portfolio elevated by updated NCCN prostate cancer guidelines - Myriad Genetics commends the updated Prostate Cancer Guidelines from the National Comprehensive Cancer Network, NCCN, as the guidelines underscore the critical role of the company's portfolio of offerings across the patient's prostate cancer journey. These guidelines further validate Myriad's ability to streamline the diagnostic process and enhance personalized treatment options.

08:20 EST Scilex Bio signs binding term sheet with NeuroBiogen - Scilex Bio, a controlling interest of joint venture by Scilex Holding Company, announced the signing of a binding term sheet with NeuroBiogen to grant Scilex Bio an exclusive worldwide license to the franchise KDS2010 drug candidate to develop and commercialize in metabolic diseases and neurodegenerative diseases, including Alzheimer's, Parkinson's and other CNS diseases. The lead program in the proposed joint venture is an oral tablet product candidate that is currently in Phase 2 trials in obesity and Alzheimer's disease indications. The term sheet provides that NeuroBiogen will grant Scilex Bio the worldwide license rights along with the rights to sublicense for all KDS2010 indications.

08:16 EST VolitionRx's Nu.Q cancer test shows efficacy in lung cancer detection - VolitionRx announced the results of a large-scale study which shows that its Nu.Q Cancer Test differentiated between malignant and benign pulmonary nodules, found by Low Dose CT or LDCT scan, in patients suspected of lung cancer. Findings published in a paper that is currently undergoing peer review and accessible on MedRXIV, conclude that a panel of two Nu.Q nucleosome quantification assays showed a diagnostic sensitivity of 92% and a Positive Predictive Value of 89% in identifying cancerous nodules when used in combination with LDCT screening. The validation study is set to begin this year and due for completion in 2025, potentially leading to the inclusion of the Nu.Q Cancer test in Taiwan's National Lung Cancer Screening Program.

08:16 EST Sirius XM expects to reduce its debt by approximately $700M in 2025 - Following the retirement of 12% of its outstanding common stock and the addition of $1.7B of debt as a result of the Liberty Media split-off transactions, the company remains committed to its leverage target of low-to-mid 3 times adjusted EBITDA. Without giving effect to any opportunistic share repurchases, SiriusXM expects to reduce its debt by approximately $700M in 2025 and achieve a leverage ratio of 3.6x by year end 2025.

08:14 EST Sirius XM targets incremental $200M of annualized savings exiting 2025 - Following the successful implementation of cost-reduction efforts across various business units as well as a period of high re-investment in product infrastructure, SiriusXM is further optimizing efficiencies in key areas across the business. The company is scrutinizing the lifetime value of subscribers, optimizing marketing efforts for higher returns, aligning content investments with its strategic and profitability goals, and closely monitoring the return on technology investments to drive greater operational efficiency and enhance the listener experience. To date, the company has delivered an aggregate of approximately $350M of run rate savings in 2023 and 2024, and will target an initial incremental $200M of annualized savings exiting 2025.

08:14 EST Microbot Medical announces FDA submission for commercialization of LIBERTY - Microbot Medical announced that it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration, FDA, for LIBERTY. LIBERTY is the world's first single-use, fully disposable robotic system for endovascular procedures. The 510(k) submission follows the successful completion of its multi-center, single-arm, trial to evaluate the performance and safety of LIBERTY in human subjects undergoing Peripheral Vascular Interventions.

08:12 EST aTyr Pharma announces third positive DSMB review for efzofitimod - aTyr Pharma announced the outcome of a third, pre-planned interim safety analysis conducted by an independent data and safety monitoring board, DSMB, for the ongoing Phase 3 EFZO-FIT study of the Company's lead therapeutic candidate, efzofitimod, in patients with pulmonary sarcoidosis. The DSMB recommended that the study continue without any modifications.

08:11 EST Novavax begins dosing in COVID-19-influence and season influenza Phase 3 trial - Novavax announced that the first participants have been dosed in its COVID-19-Influenza Combination and stand-alone seasonal influenza Phase 3 trial. The trial will evaluate the immunogenicity and safety of the CIC and stand-alone seasonal influenza vaccine candidates compared to Novavax's updated 2024-2025 COVID-19 vaccine, NVX-CoV2705, and a licensed seasonal influenza vaccine comparator in adults aged 65 and older. The company is working with the FDA to determine the potential of the current CIC and stand-alone influenza trial to support accelerated approval. Novavax anticipates being able to provide more clarity and information on potential next steps by Q2 2025, including if additional clinical work would be needed to achieve registration for these assets. The randomized Phase 3 trial builds on positive Phase 2 data and aims to further evaluate the immunogenicity and safety of a combination of Novavax's updated 2024-2025 COVID-19 vaccine, trivalent nanoparticle stand-alone seasonal influenza vaccine candidate and patented saponin-based Matrix-M adjuvant relative to separate administrations of Novavax's updated 2024-2025 COVID-19 vaccine and a licensed seasonal influenza vaccine comparator. In addition, the trial also aims to further evaluate the immunogenicity and safety of Novavax's stand-alone influenza vaccine, also containing Matrix-M. The company's FY 2025 financial guidance for combined R&D and Selling, General and Administrative expense of approximately $500M is inclusive of this CIC and stand-alone influenza initial planned Phase 3 clinical activity and is subject to revisions and updates as next steps are determined.

08:11 EST Barington Capital urges 'new leadership' at Matthews - Barington Capital Group and certain of its affiliates, a fundamental, value-oriented activist investor that beneficially owns approximately 2% of the outstanding common stock of Matthews International, sent a letter to the Chairman of Matthews' Board of Directors, Alvaro Garcia-Tunon, highlighting Barington's belief regarding the immediate need for new leadership at the company and the steps the company must take to improve long-term value for shareholders. James Mitarotonda, Chairman and CEO of Barington Capital, said, "Barington first invested in Matthews because we believed it was significantly undervalued and had the potential to deliver substantial, above market returns for its investors. We continue to believe this remains true and that the company's Memorialization business is an exceptionally valuable asset with substantial market share and strong, long-term customer relationships. Unfortunately, however, under the leadership of CEO Joseph Bartolacci, the company continues to meaningfully underperform and fall short of expectations. As a consultant to Matthews for the last two years, Barington has tried hard to work constructively with Mr. Bartolacci to reverse this underperformance. Despite our long track record of helping numerous companies unlock their potential, the company has not demonstrated meaningful progress on any of the initiatives we suggested to improve its long-term performance. We are patient, long-term investors, but we can no longer accept the status quo. We strongly believe new leadership at the management and Board levels is required to ensure the value potential of Matthews can be unlocked. It is for this reason that we have nominated three highly qualified directors for election to the Board at the Company's 2025 annual meeting of shareholders." Reference Link

08:09 EST AT&T collaborates with Madison Energy Infrastructure - AT&T has signed an agreement with Madison Energy Infrastructure to be the primary anchor tenant of four Maryland community solar sites. The projects-located in Baltimore, Glen Burnie, Upper Marlboro, and Mardela Springs-are expected to generate 12.67 MWh annually, equivalent to powering 1,174 homes.

08:08 EST Immutep announces initiation of TACTI-004 Phase III trial - Immutep announces the initiation of the pivotal TACTI-004 Phase III clinical trial for the treatment of first-line metastatic non-small cell lung cancer, 1L NSCLC. "The receipt of regulatory approval from the Australian Therapeutic Goods Administration to commence the TACTI-004 trial is a significant milestone for Immutep and marks its transformation into a Phase III company. This also represents a key step towards potentially establishing a new standard of care for patients with metastatic NSCLC. We are confident based on the strength of eftilagimod alfa's data that it can make a meaningful difference in cancer patients' lives, and we eagerly anticipate enrolling the first patient into this important study during the first quarter of 2025," said Marc Voigt, CEO of Immutep.

08:07 EST Dare Bioscience announces publication in Sexual Medicine on RESPOND study - Dare Bioscience announced that additional data from the exploratory Phase 2b RESPOND clinical study of Sildenafil Cream, 3.6%, an investigational topical cream formulation of sildenafil being developed as an on-demand treatment for female sexual arousal disorder, FSAD, has been published by Sexual Medicine, an official publication of the International Society for Sexual Medicine. The exploratory Phase 2b RESPOND study was specifically designed to identify the patient population that experienced the most meaningful improvement from Sildenafil Cream and the questions to ask them, or the patient-reported outcome measures, that best reflect that improvement. The subset analyses published by Sexual Medicine compared efficacy endpoints based on study product use in pre-planned and post-hoc subsets of age, race, and medication use to help refine target populations in future studies of Sildenafil Cream, 3.6% for the treatment of FSAD. As previously announced, safety and efficacy data from the Phase 2b RESPOND study have been published in The Journal of Sexual Medicine and Obstetrics & Gynecology, respectively:

08:07 EST Astria Therapeutics announces FDA clearance for STAR-0310 IND application - Astria Therapeutics announced the FDA clearance of its investigational new drug, or IND, application for STAR-0310, a monoclonal antibody OX40 antagonist, the company is developing as a potential treatment for atopic dermatitis (AD) and potentially other indications. A Phase 1a trial of STAR-0310 in healthy subjects is expected to initiate in the first quarter of 2025, with early proof-of-concept results expected in the third quarter of 2025. Further, the company anticipates proof-of-concept results in atopic dermatitis patients in the second quarter of 2026.

08:06 EST Compass Therapeutics appoints Shin as Chief Financial Officer - Compass Therapeutics (CMPX) announced the appointment of Barry Shin as Chief Financial Officer, as of December 9, 2024. Shin is a veteran biopharmaceutical leader with over 20 years of experience as a finance and operations executive, investment banker, and corporate advisor. Most recently, he served as Executive Vice President, Chief Operating Officer & Chief Financial Officer at Trevena (TRVN).

08:06 EST Gen Digital acquires MoneyLion for $82 per share - Gen Digital (GEN) has entered into a definitive agreement to acquire MoneyLion (ML), a leading digital ecosystem for consumer finance that empowers everyone to make their best financial decisions. Through this acquisition, MoneyLion extends Gen's identity solutions into offering comprehensive financial wellness through MoneyLion's full-featured personal finance platform that includes credit building and financial management services. The boards of both Gen and MoneyLion have unanimously approved the proposed acquisition of MoneyLion by Gen for $82.00 per share in cash payable at closing, representing a cash value of approximately $1B. In addition, for each share owned, MoneyLion shareholders will receive at closing one contingent value right that entitles the holder to a contingent payment of $23.00 in the form of shares of Gen common stock if Gen's average volume-weighted average share price reaches at least $37.50 per share over 30 consecutive trading days from December 10, 2024 until 24 months after close. There can be no assurance that any payments will be made with respect to CVRs. It is expected that the CVRs will be listed on the Nasdaq Stock Market. Closing of the proposed acquisition is expected to occur in the first half of Gen's FY26, with no impact to Gen's FY25 guidance. The acquisition is accretive to non-GAAP EPS, and the company re-affirms its commitment of net leverage below 3x EBITDA by FY27.

08:05 EST Stingray Group, K2 Studios to partner on EarthDay 365 FAST channel - Stingray announces its sales and content provisioning agreement with K2 Studios to operate and distribute the EarthDay 365 channel. This business collaboration will deliver a captivating mix of nature, conservation and science content to audiences worldwide through all of Stingray's branded services, including Free Ad-Supported Television, FAST, and Advertising Video on Demand, AVOD, platforms. "This partnership with K2 Studios represents an exciting opportunity for Stingray to broaden our content portfolio with engaging programming that captivates audiences worldwide," said Eric Boyko, President, Co-founder, and CEO of Stingray. "EarthDay 365 is more than just a channel; it's a movement towards greater awareness and action for the preservation of our planet."

08:04 EST Surf Air Mobility appoints Deanna White CEO, COO - Surf Air Mobility announced it has appointed Deanna White to the position of CEO and COO, after having served as the company's interim CEO and COO since May. White also previously served as Surf Air Mobility's CFO from May 2022 to December 2023.

08:02 EST EzFill closes on the purchase of Yoshi Mobility's fuel division - EzFill Holdings has closed on the purchase of the mobile fueling division of Yoshi, expanding EzFill's existing business into five new markets within four states. The transaction closed on Monday, December 2, 2024, and as a result EzFill has officially commenced operations in four new States: California, Michigan, Tennessee and Texas. EzFill has started the process of integrating Yoshi's assets, operations and customers into its growing infrastructure. "This notable expansion across the country and new markets marks a significant step toward achieving national operations and presence," said EzFill CEO Yehuda Levy. "We will continue to grow consistent service standards and brand visibility while leveraging economies of scale to improve efficiency and competitiveness."

07:57 EST Koppers Holdings names Chief Legal and Sustainability Officer - Koppers Holdings elected Stephanie Apostolou as Chief Legal and Sustainability Officer and Secretary for Koppers. Apostolou joined Koppers in 2011 as Corporate Counsel and subsequently served as Deputy General Counsel and Assistant Secretary before being named General Counsel and Secretary in 2020. Apostolou will continue to be responsible for all aspects of the Legal function. Additionally, as Secretary, she will continue to support and coordinate the company's Corporate Governance function and matters relating to the Board of Directors.

07:43 EST Redwire awarded $45.47M Air Force contract - Redwire was awarded a $45.47M, five-year cost-plus-fixed-fee contract that will be incrementally funded by the Air Force Research Laboratory, or AFRL, Space Vehicles Directorate for the design, development, and testing of prototype software and hardware for mission critical technologies. The contract will support the AFRL Space Vehicles Directorate's efforts to equip the joint warfighter with a spectrum of agile, effective, resilient, and affordable space mission capabilities. Redwire will research and develop novel and emerging spacecraft technologies to include large deployable structures, thermal management capabilities, payload accommodations, and improved analysis and testing methods for in-space and terrestrial national security applications. This contract builds on a previously awarded AFRL contract to mature space domain technologies from early functional proof of concept through demonstration of full system or architecture prototypes.

07:41 EST Nayax announces expanded collaboration with Discover Global Network - Nayax (NYAX) announced an expanded collaboration with Discover (DFS) Global Network, to accept Discover, Diners Club International and network alliance cards at Nayax payment devices across EMEA. This collaboration unlocks potential growth opportunities for both Nayax and Discover Global Network. Nayax enhances its customers' ability to serve 345 million Discover Global Network Cardholders1,with more than $589 billion in global spend in 2023.

07:40 EST Super Group declares EUR 0.15 special cash dividend - The company said, "In light of the company's performance, Super Group's Board of Directors has declared a special cash dividend on its ordinary shares of 15c per share, payable on January 8, 2025 to shareholders of record as of the close of business on December 23. This dividend, combined with the initial 2024 dividend of 10c per share paid in July, takes the total shareholder dividend declared for 2024 to 25c per share. The company re-iterated its intention to begin paying a regular quarterly dividend, subject to Board approval, in 2025."

07:32 EST Lindblad Expeditions appoints Natalya Leahy as CEO, Rick Goldberg as CFO - Lindblad Expeditions announced two key executive appointments: Natalya Leahy will join as CEO, effective Jan. 1, 2025, and Rick Goldberg has been appointed CFO, effective Dec. 31, 2024. Leahy most recently served as President of Seabourn. Prior to taking on the role of President, Leahy spent several years serving in various leadership positions at Holland America Group, including COO and CFO, respectively. Throughout her career, Leahy served in various leadership roles for global organizations, such as Procter & Gamble, United Nations, and Coca-Cola. Goldberg currently serves as CFO of Founders Table Restaurant Group. Previously, Goldberg also held various leadership positions, including CFO, at Jackson Hewitt Tax Service. Leahy succeeds Lindblad Expeditions' Founder, Lindblad, who will become Founder and Co-Chair of the Board. Ein will become Board Co-Chair as well as Lead Independent Director. Rick Goldberg succeeds L. Dyson Dryden, who has served as interim CFO since June 2024, and continues his position as a Board Director.

07:31 EST Virax Biolabs enters non-exclusive distribution agreement with Tebubio - Virax Biolabs announced that it has entered into a non-exclusive distribution agreement with French company Tebubio to expand the distribution of its ImmuneSelect Research Use portfolio into countries in the European Union, as well as in Norway and Switzerland.

07:22 EST uniQure announces alignment with FDA on elements of approval path for AMT-130 - uniQure N.V. announced that the company reached agreement with the U.S. Food and Drug Administration, FDA, on key elements of an Accelerated Approval pathway for AMT-130. As part of uniQure's Regenerative Medicine Advanced Therapy Type B meeting held in late November, the FDA agreed that data from the ongoing Phase I/II studies, compared to a natural history external control, may serve as the primary basis for a BLA submission under the Accelerated Approval pathway, avoiding the need for an additional pre-submission study. The FDA also agreed that cUHDRS may be used as an intermediate clinical endpoint and that reductions in neurofilament light chain measured in cerebrospinal fluid may serve as supportive evidence of therapeutic benefit in the application for accelerated approval.

07:21 EST Better Choice Company increases capital stock distribution of Halo - Better Choice announced that as part of the acquisition of SRx Health Solutions, the capital stock distribution of Halo, Purely for Pets has increased from an 8% to 17% dividend. The closing of the transaction is subject to customary closing conditions, including the receipt of required shareholder approvals from SRx Health and Better Choice. The transaction is expected to close during the first quarter of 2025.

07:19 EST PricingDirect and Aumni Partner team for independent valuations for PE - PricingDirect and Aumni both wholly owned subsidiaries of JPMorgan Chase are pleased to announce a strategic partnership aimed at providing investors with independent valuations of private equity securities. This collaboration leverages the strengths of both entities to offer a comprehensive solution that enhances transparency and efficiency in the valuation process, helping investors navigate the complexities of private equity investments. By combining PricingDirect's expertise in evaluated pricing and Aumni's private market expertise and advanced data analytics capabilities, the partnership offers investors the ability to receive valuations that are both reliable and aligned with industry standards. "In the past few years, we've witnessed a significant increase in allocations to alternative assets. With over two decades of valuation experience in public markets, we are delighted to deliver solutions for private equity valuations to managers and allocators," said Neil Hyman, CEO of PricingDirect. "With the powerful combination of PricingDirect's valuation expertise and Aumni's leading private market data structuring capabilities and insights, we can bring streamlined and tech-enabled capabilities to private markets participants," Hyman added.

07:16 EST Mobilicom secures production orders from U.S. customer - Mobilicom announced it has secured its latest initial production-scale orders for its cybersecure SkyHopper Pro datalinks from an innovative U.S.-based drone designer and manufacturer that serves commercial and defense customers globally. "We continue to expand our deployment presence in the U.S. market's defense and commercial sectors through our customer base. These highly innovative high-payload long-range drones operate in assured performance in tough conditions and our SkyHopper Pro plays an essential part in their communications capabilities. We anticipate additional production scale orders from this customer as these drones are adopted by a growing number of end users," stated Mobilicom CEO Oren Elkayam.

07:14 EST Beneficient hires Jones as Managing Director of Capital Markets - Beneficient announced the hiring of Louise Jones as Managing Director of Capital Markets and Custody Operations.

07:12 EST Lantronix to hold one-on-one briefings during CES to preview solutions - Lantronix announced that it will host a suite at the Wynn Tower Suites during CES, Jan. 7-10, 2025, to share its 2025 product roadmap of Edge AI solutions. "Our presence at this year's CES provides us with the opportunity to share with customers and channel partners our integrated, collaborative Edge AI solutions that drive real-time decision making for businesses involved in the Smart City, Enterprise and Transportation industries," said Saleel Awsare, CEO of Lantronix.

07:11 EST NewAmsterdam reports data from Phase 3 BROADWAY trial, met primary endpoint - NewAmsterdam Pharma announced positive topline data from the Company's Phase 3 BROADWAY clinical trial evaluating obicetrapib in adult patients with established atherosclerotic cardiovascular disease, ASCVD, and/or heterozygous familial hypercholesterolemia, HeFH, whose LDL-C is not adequately controlled, despite being on maximally tolerated lipid-lowering therapy. The primary endpoint was the least-squares mean of the percent change in LDL-C from baseline to day 84 for obicetrapib 10 mg compared to placebo, using imputation for missing data. The primary endpoint was achieved with statistical significance with an LDL-C reduction of 33%

07:06 EST Vince Holding :Transformation Program expected to result in $30M in savings - On October 31, the Company announced its Transformation Program focused on driving enhanced profitability through an improved gross margin profile and an optimized expense structure. The Transformation Program is expected to result in over $30 million in savings over the next three years, including approximately $10 M of savings in fiscal 2024. As of the end of the third quarter of fiscal 2024, the Company is ahead of its plan to achieve its fiscal 2024 target.

07:04 EST OnKure Therapeutics announces safety, pharmacokinetic data on OKI-219 - OnKure Therapeutics announced encouraging safety, tolerability, and pharmacokinetic data from the ongoing first-in-human trial of OKI-219, a potential best-in-class, mutant-selective PI3KalphaH1047R inhibitor. OKI-219 was well tolerated across all dose levels with no hyperglycemia, and only grade 1 treatment-related adverse events were reported. No dose interruptions, delays, reductions, or discontinuations were reported for any adverse events. OKI-219 dosed at 900 mg twice daily shows steady-state exposure levels with near-continuous coverage of the in vivo EC 80 for pAKT inhibition. These data are consistent with the Company's preclinical data and support the continued development of OKI-219. Initial patient data show exposures of OKI-219 exceeding levels associated with robust antitumor activity in preclinical models; Data support the initiation of Part 1b of PIKture-01 evaluating OKI-219 in combination with fulvestrant; first patients dosed, and initial data are expected in 2H-2025.

07:02 EST IN8bio announces updated data for Phase 1 trial of INB-100 - IN8bio announced updated data from the ongoing Phase 1 trial of INB-100, an allogeneic, haploidentical gamma-delta T cell therapy in older patients with hematologic malignancies undergoing haploidentical stem cell transplant, HSCT, with reduced intensity conditioning, RIC, at the 2024 American Society of Hematology, ASH, Annual Meeting, being hosted in San Diego, CA. In a poster presentation, IN8bio reported that there have been no newly reported deaths or relapses as of September 30, 2024. As of that cutoff date, median CR was at 16.4 months following a median of 19.2 months of follow-up. As previously reported, all patients remained alive, progression-free, and in durable CR through one-year. 100% of AML patients remain in CR after a median 19.7 months of follow-up with three patients with high-risk cytogenetic AML and receiving no maintenance therapy remaining in mCR for greater than three years.

06:57 EST AutoZone CEO says 'we are well positioned for growth' - "I would like to thank all our AutoZoners across the globe for their efforts in helping us deliver solid first quarter results. We were pleased with the progress in our DIY same store sales result from the prior quarter as average ticket and traffic trends improved. Our domestic Commercial sales were up 3.2% and we were encouraged by the improving trends seen at the end of the quarter. Our international businesses continued to perform well with same store sales up just under 14% on a constant currency basis. While currency rate moves depressed reported sales and earnings growth, our international performance remains encouraging as we continue to focus on opening more stores in these markets. We feel we are well positioned for growth heading into the remainder of the fiscal year, as we believe the initiatives we have in place to improve customer service and grow market share are on track. As we continue to invest in our business, we remain committed to our disciplined approach of a focus on increasing earnings and operating cash flow, all while delivering strong shareholder value," said Phil Daniele, President and Chief Executive Officer. During the quarter ended November 23, 2024, AutoZone opened 23 new stores in the U.S., six in Mexico and five in Brazil for a total of 34 new stores. As of November 23, 2024, the Company had 6,455 stores in the U.S., 800 in Mexico and 132 in Brazil for a total store count of 7,387.

06:51 EST The Buckle declares $2.50 per share special cash dividend - The Buckle authorized a $2.50 per share special cash dividend to be paid to shareholders of record at the close of business on January 15, 2025. The Board also authorized a 35c per share quarterly dividend to be paid to shareholders of record at the close of business on January 15, 2025. Both the $2.50 per share special cash dividend and the 35c per share quarterly dividend - $2.85 per share in total - are payable on January 29, 2025 and will be paid together.

06:48 EST Lazard reports November 2024 AUM of $234.4B - Lazard reported preliminary assets under management - AUM - as of November 30, 2024 totaled approximately $234.4B. The month's AUM included market appreciation of $3.0B, net outflows of $2.3B and foreign exchange depreciation of $2.2B.

06:33 EST Babcock & Wilcox BrightLoop project to be funded by state of West Virginia - Babcock & Wilcox Enterprises announced that one of its subsidiaries has signed an agreement for funding of up to $10M from the West Virginia Department of Economic Development for the development of a BrightLoop hydrogen production and carbon capture facility in Mason County, W. Va. The memorandum of agreement between B&W's wholly-owned Mountaineer C2H, LLC subsidiary and the state provides performance-based financial and economic development assistance for the development of a low-carbon-emissions hydrogen production facility that uses B&W's BrightLoop chemical looping technology and is powered by coal and biomass. The $10M in funding will be phased in upon achievement of project milestones.

06:32 EST Brown & Brown subsidiary acquires assets of ARMR - J. Scott Penny, chief acquisitions officer of Brown & Brown, and David Dybdahl and Cynthia Statz, owners of American Risk Management Resources Network, announced that a Bridge Specialty Group company and subsidiary of Brown & Brown, Inc. has acquired the assets of ARMR. ARMR is a specialty wholesale environmental insurance brokerage platform serving production partners nationwide.

06:23 EST Hepsiburada sees Q4 gross merchandise value growth of 50%-55% year-over-year - Sees Q4 EBITDA as percentage of gross merchandise value 1.8%-2.0%.

06:17 EST Alaska Air launches new global gateway in Seattle, unveils new routes - Alaska Air announced the launch of Seattle as a new global gateway. New nonstop service with Hawaiian Airlines widebody aircraft between Seattle and Tokyo Narita, Japan and Seoul Incheon, South Korea will begin in 2025, and an enhanced domestic network for the two airlines will launch this spring. Daily nonstop flights between Seattle and Tokyo Narita start on May 12, 2025, offering guests an option when traveling between the Pacific Northwest and Japan on Hawaiian's Airbus A330-200 aircraft. These flights, along with connections to other Asian destinations on oneworld Alliance partner Japan Airlines, can be purchased now. Nonstop service between Seattle and Seoul Incheon is scheduled to begin in October 2025, with fares available for purchase early next year, along with additional flight details. Air Group's Seattle hub is the largest on the West Coast of any carrier, serving 104 nonstop destinations across North America. Including Tokyo Narita and Seoul Incheon, the company plans to serve at least 12 nonstop global destinations with long-haul widebody aircraft from our Seattle gateway by 2030, with further specifics on where and when to be revealed later. The company said, "We are also enhancing our newly combined domestic network with strategic changes to where, when and what type of aircraft we fly. Our primary goals are to improve performance, expand growth opportunities, and offer our guests increased choice, network connectivity and convenience. The adjustments begin to take effect in late March with our spring schedule and continue to roll out through the second quarter: More choices for our guests flying between the West Coast and Hawai?i: We're updating our departures to improve our time-of-day coverage. We will offer 20% more seats between Seattle and Honolulu, with three of our six daily nonstop flights from Seattle to Honolulu on widebody Hawaiian aircraft. This helps us accommodate an expected increase in passenger and cargo demand. In Portland, there will be three daily nonstops to Honolulu with convenient staggered departure times and a 25% increase in available seats. We're also improving connectivity in San Diego - a growing West Coast gateway to Hawai?i for Air Group - with mid-morning and late afternoon departures to Maui instead of just morning departures, and newly timed mid-afternoon and redeye departures from Maui. Improved connectivity for East Coast and Midwest flights to Hawai'i: We will offer an adjusted flight schedule using our combined network to allow for flights from the East Coast and Midwest to connect more easily on the West Coast before heading to the Islands. In addition to the new redeye between Maui and San Diego, we are adding three more overnight flights from Hawai?i to the West Coast: Honolulu and Maui to Portland, and Honolulu to San Francisco. The redeye flights unlock new connections for our flyers across the continental U.S. and will boost the utilization of Hawaiian aircraft. Improved connectivity will open greater access to Hawai'i for guests throughout our network and strengthen nonstop and one-stop access to destinations across North America for Hawai'i residents. Maximizing widebody flying: To accommodate additional guests, we will fly Hawaiian's larger A330 aircraft on three flights between Honolulu and Seattle and move to one daily flight with an A330 between Honolulu and Sacramento. During the peak summer season in the state of Alaska, we will deploy Hawaiian A330 aircraft to fly between Seattle and Anchorage to take advantage of the aircraft's higher seating and cargo capacity. Alaska and Hawaiian have complementary cargo networks, with cargo playing a crucial role in the communities they serve. Alaska will fly at least 18 daily roundtrips this summer between Seattle and Anchorage. New nonstops between San Francisco and the Islands: We're adding new nonstops on Alaska between San Francisco and both Kona on Hawai'i Island and Lihu'e on Kaua?i. San Francisco-Kona service will be four times a week starting June 12, 2025, and San Francisco-Lihu?e will be three times a week starting June 13, 2025. With these new flights, Alaska and Hawaiian will offer four daily nonstop flights to the four main Hawaiian Islands from San Francisco, one of our key West Coast hubs. The new flights are available for purchase now at alaskaair.com and hawaiianairlines.com. Adding more flying with the Hawaiian brand: To better utilize the fleet, we've increased the number of hours Hawaiian's Boeing 787-9 and Airbus A321 aircraft fly daily. This means more flying time for Hawaiian's crews and more union jobs. The A321s will fly 25% more than they did before. This strategy mitigates the impact of delayed Boeing 737 deliveries while enabling us to expand our overall network reach. Alaska and Hawaiian continue to work on obtaining a single operating certificate from the Federal Aviation Administration (FAA), a process that is expected to be completed by October 2025. Each airline will operate separately until the certificate is issued. Even with the combination into one great airline, the company will keep the two brands our guests love so much."

06:09 EST Alaska Air introduces 'Alaska Accelerate', 2027 targets at investor day - Alaska Air will host its previously announced investor day at 1 p.m. Eastern time in New York City. In its first presentation since acquiring Hawaiian Airlines, the company will unveil Alaska Accelerate, its vision for the combined company, including how it will power commercial performance and achieve medium-term financial targets. Significant investments in the commercial organization revolve around four main goals: enabling the power of an expanded network by opening a global gateway in Seattle with long-haul widebody aircraft, blending two route networks to optimize connections as Alaska and Hawaiian now operates over 1,400 daily flights to over 140 cities; providing Hawai'i residents access to an expanded network and a dedicated loyalty program; investing in its existing end-to-end premium experience including enhanced airport lobbies and lounges in hubs, expanded premium seat capacity, a new loyalty platform and a premium credit card offering. The company's new 2027 financial targets will include: $1B in incremental profit; earnings per share of at least $10; double digit pretax profit margins 11%-13%; no margin dilution in year one following the merger and synergy estimates doubled to at least $500M.

06:04 EST Joby Aviation, Jetex announce strategic partnership - Joby Aviation and Jetex announced a strategic partnership to redefine seamless connectivity for Jetex customers. The two companies will focus initially on Jetex locations across the Middle East, where Joby plans to install its Global Electric Aviation Charging System to support Joby operations that will connect Jetex passengers to a network of vertiports, offering efficient and sustainable travel across the region and between Emirates.

05:39 EST Metagenomi presents updated preclinical NHP data at ASH meeting - Metagenomi presented updated preclinical NHP data for its hemophilia A program in an oral presentation at the American Society of Hematology, or ASH, 66th Annual Meeting and Exposition in San Diego. In a preclinical study, a cynomolgus version of the FVIII gene, used to avoid the confounding effects of anti-human FVIII antibodies, was administered to three NHPs via AAV at a dose of 2.0E13 vg/kg. Five weeks later, each NHP was administered an LNP at a dose of 1.0 mg/kg, delivering the MG29-1 nuclease mRNA and associated guide RNA. Each animal received only a single dose of dexamethasone prior to the AAV and LNP doses. Plasma was collected and assayed for safety parameters and FVIII activity. Data was generated over 16 months and the study remains ongoing. Results of the study suggest that FVIII activity was maintained over the 16-month study duration. Mean FVIII activity of months 13-16.5 following LNP dosing was 71%, 7%, and 27% compared to mean FVIII activity of months 3-6 of 76%, 8% and 30%, and mean FVIII activity of months 7-12 of 77%, 8% and 32% respectively, in animals 1001, 1002 and 1003. At the 16.5-month time point, FVIII levels were 72%, 9%, 30% in each of the three animals, respectively. FVIII activity levels correlated with gene integration frequency from day 7 liver biopsy of 0.7%, 1.3%, 3.1% in each of the three animals, respectively. The FVIII knock-in was achieved with only transient elevation of liver transaminases at the time of AAV and LNP administration, and with no other safety findings and no impact to circulating albumin levels and no significant change in total bilirubin post AAV and LNP. A separate NHP study designed to support the company's lead hemophilia A development candidate, MGX-001, which uses a B-domain deleted bioengineered FVIII construct, demonstrated significantly higher FVIII activity compared to wild type FVIII, despite similar integration frequency between the bioengineered construct and wild type gene. This result suggests the MGX-001 bioengineered construct may enable therapeutic FVIII activity at lower AAV doses with the potential for associated safety benefits. In addition, MGX-001 showed no identifiable off-target editing to-date in a series of orthogonal assays employed to discover and validate potential off-target sites.

05:33 EST On Semiconductor to acquire SiC JFET business from Qorvo for $115M in cash - On Semiconductor (ON) announced that it has entered into an agreement to acquire the Silicon Carbide Junction Field-Effect Transistor, or SiC JFET, technology business, including the United Silicon Carbide subsidiary, from Qorvo (QRVO) for $115M in cash. SiC JFETs offer the lowest on-resistance per chip area, using less than half of any other technology. They also allow for the use of typical off-the-shelf drivers, which have been deployed with silicon-based transistors for decades. Together, these benefits result in faster development, reduced energy consumption and lower system costs. The transaction is subject to customary closing conditions and is expected to be finalized in the first quarter of 2025.

05:26 EST ASE Technology reports November revenue $1.66B, down 2.6% - Reports November ATM revenue $909M, up 6.6%.

05:08 EST PCC Group to build chlor-alkali facility on Chemours Dallas TiO2 plant grounds - Chemours announced that the PCC Group plans to build and operate a chlor-alkali facility on the grounds of Chemours' titanium dioxide, or TiO2, plant in DeLisle, Mississippi and that PCC and Chemours have entered into a chlorine supply agreement which is subject to certain customary conditions precedent. The new facility will utilize technology to maximize energy efficiency and provide up to an annual nameplate capacity of 340,000 metric tons once the plant is operational. The co-product, caustic soda, will be sold by PCC to strategic partners and on the open market. Construction is expected to begin in early 2026 with the plant being operational in 2028. The project will create full-time opportunities for skilled personnel with PCC, and up to 1,200 temporary construction jobs.